Customer orders for Illumina’s qPCR portfolio through VWR will be accepted starting December 1, 2012.About Illumina Illumina ( www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Illumina, Inc. (NASDAQ:ILMN) today announced that VWR International, LLC, a global distributor of laboratory supplies and services, will distribute Illumina’s qPCR portfolio including the Eco™ Real-Time PCR System and NuPCR™ reagents within the United States, one of the world’s largest qPCR instrumentation markets. The agreement extends Illumina’s reach for its innovative Eco System and novel NuPCR probe-based technology into thousands of laboratories and facilities nationwide, by leveraging VWR’s 150 years of industry experience and its well-established distribution network. “Complementing Illumina’s commercialization efforts with VWR’s talented team of sales and services representatives enables us to significantly expand promotion and support of both the Eco System and NuPCR reagents in molecular biology laboratories throughout the United States,” said Mark Lewis, Senior Vice President and General Manager of Illumina’s Molecular Biology and PCR Business. “We are very excited to join forces with VWR to accelerate adoption of our qPCR portfolio, particularly into the pharmaceutical and industrial markets where VWR has a strong presence.” Real time PCR is a precise, highly sensitive PCR method with applications in basic research and diagnostics, where, for example, it is used for quantitation of gene expression targets, verification of array data, and pathogen detection. Illumina’s Eco Real-Time PCR System is an affordable, compact instrument that allows researchers to perform any qPCR application directly on their bench top and is an economical alternative to traditional large, expensive PCR instruments. The company’s novel, NuPCR probe-based qPCR technology is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies on the market today. It is compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation. “Illumina’s qPCR portfolio adds tremendous value to our existing PCR solutions portfolio,” said Bill Molnar, Vice President of Category Management, Life Sciences, VWR. “Both of our companies are committed to enabling the world’s scientists to accelerate research. The addition of the Eco System and NuPCR reagents provides an essential element to our product line, empowering us to effectively support key customer segments.”